Xenon Pharmaceuticals Inc.
XENE
$34.70
-$0.41-1.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -234.33M | -213.39M | -199.06M | -188.60M | -182.39M |
| Total Depreciation and Amortization | 2.56M | 1.30M | 2.36M | 2.31M | 2.06M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 44.67M | 46.42M | 36.48M | 28.73M | 23.32M |
| Change in Net Operating Assets | 5.71M | 3.27M | 883.00K | -2.31M | 5.90M |
| Cash from Operations | -181.39M | -162.41M | -159.34M | -159.88M | -151.11M |
| Capital Expenditure | -3.08M | -2.37M | -2.98M | -3.60M | -5.62M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 168.08M | -170.92M | -118.41M | -200.61M | -105.77M |
| Cash from Investing | 165.00M | -173.29M | -121.39M | -204.21M | -111.39M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.13M | 324.01M | 353.52M | 353.52M | 353.52M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 12.13M | 324.01M | 353.52M | 353.52M | 353.52M |
| Foreign Exchange rate Adjustments | -1.67M | -269.00K | -611.00K | -50.00K | 376.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -5.93M | -11.95M | 72.18M | -10.62M | 91.40M |